Digitisation | August 13, 2021
Labcorp, a leader in women’s heath solutions acquires Ovia Health
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Acquisition of A&C expands Aceto’s Western manufacturing footprint
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Subscribe To Our Newsletter & Stay Updated
